These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36691306)

  • 21. Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
    Blakely KK; Weaver K
    Nurs Womens Health; 2020 Oct; 24(5):370-376. PubMed ID: 32890462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
    Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
    Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
    Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
    JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical review of subcutaneous semaglutide for obesity.
    Phillips A; Clements JN
    J Clin Pharm Ther; 2022 Feb; 47(2):184-193. PubMed ID: 34964141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The glucagon-like peptide-1 receptor-agonist semaglutide].
    Boje AD; Juhl CR; Torekov SS; Madsbad S
    Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 28. The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials.
    Alabduljabbar K; Al-Najim W; le Roux CW
    Nutrients; 2022 May; 14(11):. PubMed ID: 35684020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
    Amaro A; Skolnik NS; Sugimoto D
    Postgrad Med; 2022 Jan; 134(sup1):18-27. PubMed ID: 36691308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semaglutide: First Global Approval.
    Dhillon S
    Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
    O'Neil PM; Rubino DM
    Postgrad Med; 2022 Jan; 134(sup1):28-36. PubMed ID: 36691307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.
    Zhong P; Zeng H; Huang M; Fu W; Chen Z
    Endocrine; 2022 Mar; 75(3):718-724. PubMed ID: 34981419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
    Jendle J; Birkenfeld AL; Polonsky WH; Silver R; Uusinarkaus K; Hansen T; Håkan-Bloch J; Tadayon S; Davies MJ
    Diabetes Obes Metab; 2019 Oct; 21(10):2315-2326. PubMed ID: 31215727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semaglutide as a promising antiobesity drug.
    Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
    Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.
    Mares AC; Chatterjee S; Mukherjee D
    Curr Opin Cardiol; 2022 Jul; 37(4):350-355. PubMed ID: 35175229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.